Daewoong Pharmaceutical's bio new drug research and development subsidiary HANALL BIOPHARMA announced on the 30th that its consolidated sales for the second quarter this year rose 28.8% compared to the same period last year, reaching 40.7 billion won. During the same period, operating profit and net profit were recorded at 1.1 billion won and 600 million won, respectively.
Cumulative sales for the first half were 76.8 billion won, an increase of 17% compared to the previous year, while operating profit and net profit turned to surplus at 800 million won and 400 million won, respectively.
The company stated that sales of key products in the pharmaceutical sector increased uniformly. The probiotic drug "BioTop" saw its sales more than double compared to the previous year, surpassing 10 billion won in the first half. The company noted that this product has maintained the top position in the non-reimbursable outpatient prescriptions for digestive aids for four consecutive years since 2021.
The company also explained that key product lines such as the prostate cancer treatment "Eligard," non-absorbable antibiotic "Normix," and hair loss treatment "Hairgrow Tablet" have shown steady growth, strengthening a stable sales base.
In the first half of this year, possibilities were confirmed in the research and development sector as well. The drug HL161BKN, developed by HANALL BIOPHARMA, which transferred global rights to Immunovant in 2017, showed excellent results in reducing autoantibody levels and treatment response rates in the Phase 3 clinical trial for myasthenia gravis (MG) in March, confirming its potential as a leading treatment in its class. The effectiveness of symptom improvement was also confirmed in the Phase 2b trial for chronic inflammatory demyelinating polyneuropathy (CIDP) that was disclosed together.
Partner company Immunovant is expected to secure data on the 6-month treatment-free remission after discontinuation of the Phase 2 clinical trial for Graves’ disease (GD) and the results of the Phase 3 clinical trial for thyroid eye disease (TED) in the second half. HL161BKN is proceeding simultaneously with clinical studies for six diseases based on the successful clinical data of batoclimab, which started last year.
Jeong Seung-won, CEO of HANALL BIOPHARMA, noted, "Despite external uncertainties, we achieved sales growth, and pipeline development is progressing smoothly," adding, "In the coming three years, eight clinical results in autoimmune diseases are scheduled, including the Phase 3 clinical trial for batoclimab for thyroid eye disease this year and the Phase 3 clinical trial for dry eye treatment next year." He also stated, "We will focus our capabilities on the development of new treatments, including Parkinson's disease treatments and anti-aging therapies."